Sorafenib-Induced Pancreatitis-Reference-Cited by-同舟云学术

Sorafenib-Induced Pancreatitis

Published:2007-04 Issue:4 Volume:82 Page:521
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Amar Surabhi,Wu Kevin J.,Tan Winston W.

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis;Wilhelm;Cancer Res,2004

2. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract];Escudier;J Clin Oncol,2005

3. Nevaxar (sorafenib) [package insert],2006

4. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors;Strumberg;J Clin Oncol,2005

5. Platelet-derived growth factor and transforming growth factor-beta enhance tissue repair activities by unique mechanisms;Pierce;J Cell Biol,1989

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-Induced Acute Pancreatitis: An Evidence-Based Classification (Revised);Clinical and Translational Gastroenterology;2023-07-14

2. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations;PLOS ONE;2020-04-17

3. Sorafenib-induced Pancreatic Pseudocyst in a Patient with Advanced Hepatocellular Carcinoma: a Rare Adverse Event;Journal of Liver Cancer;2019-09-30

4. Sorafenib-Induced Acute Pancreatitis in a Patient with Differentiated Thyroid Cancer;European Thyroid Journal;2018

5. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies;Journal of Hepatocellular Carcinoma;2017-07